Novo Nordisk India has cut prices of its once-weekly obesity drug Wegovy (semaglutide) by 37%, bringing the starting dose down to ₹2,712 per week. The move aims to make evidence-based obesity treatment more affordable in India, where over 250 million people live with obesity. Experts say it could expand access but is unlikely to immediately dent demand for Eli Lilly’s Mounjaro, priced at ₹14,000–₹17,500 per month. Mounjaro had emerged as the largest-selling drug in India by value in October. India’s anti-obesity market, now pegged at ₹3,500 crore, is projected to touch ₹25,000 crore by 2030 as new drugs redefine chronic weight management.

See Full Page